Future challenges for microsomal transport protein inhibitors

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Pharmacology

Background:

• Atherosclerosis poses a significant global health burden, with statins as primary lipid-lowering agents.
• Residual cardiovascular risk persists despite statin therapy, linked to high-density lipoprotein cholesterol and triglyceride levels.
• Microsomal transfer protein (MTP) plays a key role in lipoprotein assembly, making it a therapeutic target.

Purpose of the Study:

• To explore novel therapeutic strategies targeting MTP to reduce residual cardiovascular risk.
• To evaluate the efficacy and limitations of MTP inhibition in managing dyslipidemia.

Main Methods:

• Preclinical studies demonstrated MTP inhibition's profound effects on reducing triglycerides and cholesterol.
• Clinical efficacy was confirmed in humans using small molecule inhibitors and antisense oligonucleotides targeting MTP.
• Investigated lower doses or non-systemically absorbed MTP inhibitors to mitigate side effects.

Main Results:

• MTP inhibition effectively reduces blood triglycerides and cholesterol levels.
• Small molecule MTP inhibitors showed clinical efficacy but were limited by hepatic steatosis.
• Alternative MTP inhibition strategies aim to maintain efficacy while improving safety profiles.

Conclusions:

• MTP inhibition is a viable strategy for lowering lipids and addressing residual cardiovascular risk.
• Managing MTP inhibitor-induced hepatic steatosis is crucial for clinical utility.
• Further research into optimized MTP inhibition approaches is warranted to improve cardiovascular outcomes.